MET and Peripheral edema: Peripheral edema is commonly reported with MET inhibitors in 21%-50% of patients treated with capmatinib, 51% with crizotinib, 26%-63% with tepotinib, 21%-54% with savolitinib, and 18% with amivantamab.40,43,83